肿瘤细胞治疗研究
英文原题：CAR-NK cells for haematological cancers.
嵌合抗原受体自然杀伤（CAR-NK）细胞是一种有前景的癌症细胞疗法。
嵌合抗原受体自然杀伤（CAR-NK）细胞是一种有前景的癌症细胞疗法。CAR-NK细胞的若干特征提示其优于CAR-T细胞，例如制造工艺更简单、“现货型”使用以及细胞因子释放综合征（CRS）和免疫效应细胞相关神经毒性综合征（ICANS）的风险更低。来源于多种来源的CAR-NK细胞在血液系统恶性肿瘤中已取得有前景的临床前和临床结果。我们全面讨论了CAR-NK细胞疗法在血液系统恶性肿瘤中的当前格局，重点强调近期进展和未来方向。此外，我们还探讨了CAR-NK细胞的生物学机制、工程改造和来源。CAR-NK细胞疗法为血液系统恶性肿瘤提供了一种安全、可及且有效的选择。
Chimeric antigen receptor-natural-killer (CAR-NK)-cells are a promising cancer cell therapy. Several features of CAR-NK-cells are suggesting an advantage over CAR-T-cells such as less complex manufacturing, "off-the-shelf" use and lower risks of cytokine release (CRS) and immune effector cell-associated neurotoxicity syndromes (ICANS). CAR-NK-cells derived from several sources are associated with promising pre-clinical and clinical results in haematological cancers. We comprehensively discuss the current landscape of CAR-NK-cell therapy in haematological cancers emphasizing recent progress and future directions. Additionally, we explore the biological mechanisms, engineering and sources of CAR-NK-cells. CAR-NK-cell therapy offers a safe, accessible and efficient option for haematological cancers.
MEMBER ACCOUNT
登录成功会直接打开下一页。
